Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 38.81 USD 2.51% Market Closed
Market Cap: 3.2B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Verona Pharma PLC
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verona Pharma PLC
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Verona Pharma PLC
NASDAQ:VRNA
Cash from Investing Activities
-$45k
CAGR 3-Years
74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Cash from Investing Activities
ÂŁ398m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-7%
AstraZeneca PLC
LSE:AZN
Cash from Investing Activities
-$7.6B
CAGR 3-Years
-295%
CAGR 5-Years
-379%
CAGR 10-Years
-1%
Indivior PLC
LSE:INDV
Cash from Investing Activities
$32m
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Cash from Investing Activities
-$320m
CAGR 3-Years
-4%
CAGR 5-Years
-27%
CAGR 10-Years
-10%
Dechra Pharmaceuticals PLC
LSE:DPH
Cash from Investing Activities
-ÂŁ426.2m
CAGR 3-Years
-74%
CAGR 5-Years
-12%
CAGR 10-Years
-36%
No Stocks Found

Verona Pharma PLC
Glance View

Market Cap
3.2B USD
Industry
Pharmaceuticals

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.

VRNA Intrinsic Value
15.98 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

What is Verona Pharma PLC's Cash from Investing Activities?
Cash from Investing Activities
-45k USD

Based on the financial report for Sep 30, 2024, Verona Pharma PLC's Cash from Investing Activities amounts to -45k USD.

What is Verona Pharma PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
74%

The average annual Cash from Investing Activities growth rates for Verona Pharma PLC have been 74% over the past three years .

Back to Top